Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, High-Risk Non-Muscle-Invasive Bladder Cancer, +9 more
- Locations
-
- Mayo Clinic Arizona Phoenix, Arizona, United States
- Arizona Urology Specialty Tucson, Arizona, United States
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
- Arkansas Urology Little Rock, Arkansas, United States